C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 4, 2005, Pages 717-722

  Van Tits, Lambertus ^a,b   De Graaf, Jacqueline ^a   Toenhake, Helga ^a   Van Heerde, Waander ^a   Stalenhoef, Anton ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Annexin; Binding; C reactive protein; Fc receptors; Oxidized LDL

Indexed keywords

C REACTIVE PROTEIN; CD64 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; LIPOCORTIN 5; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID DERIVATIVE;

ARTICLE; BINDING AFFINITY; CALCIUM BINDING; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; OXIDATION; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ANNEXIN A5; ANTIBODIES, MONOCLONAL; BINDING SITES; C-REACTIVE PROTEIN; ELECTROCHEMISTRY; EPITOPES; HUMANS; IODINE RADIOISOTOPES; LIPOPROTEINS, LDL; PHAGOCYTES; PHOSPHOLIPIDS; RECEPTORS, IGG; U937 CELLS;

EID: 16244407441     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000157979.51673.2c     Document Type: Article

References (35)

1. Koenig W, Rottienbacher D, Hoffmeister A, Miller M, Bode G, Adler G, Hombach V, Marz W, Pepys MB, Brenner H. Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin- associated protein A-positive strains and absence of a systemic inflammatory response. Circulation. 1999; 100:2326-2331.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
3. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-1051.
4. Ishikawa T, Imamura T, Hatakeyama K, Date H, Nagoshi T, Kawamoto R, Onitsuka H, Matsuyama A, Matsuo T, Asada Y, Eto T. Production of C-reactive protein in the coronary plaque and release into coronary circulation. Circulation 2002;106(19Suppl II):346. Abstract.
5. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
6. Verma S, Li S-H, Badiwala MV, Wiesel RD, Mickle DAG, Scewart DJ. Unravelling the mechanistic basis of the CRP-atherosclerosis connection: novel role of nitric oxide and endothelin-1. Circulation 2002;106(19Suppl II):249. Abstract.
7. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043-13048.
8. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure Fold Des. 1999;7:169-177.
9. de Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med. 1982;156:230-242.
10. Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol. 1985;27:83-111.
11. Rowe IF, Soutar AK, Trayner IM, Baltz ML, de Beer FC, Walker L, Bowyer D, Herbert J, Feinstein A, Pepys MB. Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins. J Exp Med. 1984;159:604-616.
12. Bodman-Smith KB, Melendez AJ, Campbell I, Harrison PT, Allen JM, Raynes JG. C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (Fc gamma RI). Immunology. 2002;107:252-260.
13. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103:1194-1197.
14. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 1999;19:2348-2354.
15. Andree HA, Reutelingsperger CP, Hauptmann R, Hemker HC, Hermens WT, Willems GM. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem. 1990;265:4923-4928.
16. Reutelingsperger CP, Hornstra G, Hemker HC. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem. 1985;151:625-629.
17. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation. 1997;96:2339-2347.
18. Kaneko N, Matsuda R, Hosoda S, Kajita T, Ohta Y. Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. Clin Chim Acta. 1996;251:65-80.
19. van Heerde WL, Lap P, Schoormans S, de Groot PG, Reutelingsperger C, Vroom T. Localization of annexin A5 in human tissues. Annexins. 2004;1:e56-e62.
20. Van Tits L, de Graaf J, Hak-Lemmers H, Bredie S, Demacker P, Holvoet P, Stalenhoef A. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab Invest. 2003;83:13-21.
21. Haberland ME, Fogelman AM, Edwards PA. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci U S A. 1982;79:1712-1716.
22. van Heerde WL, Reutelingsperger CP, Maassen C, Lux P, Derksen RH, de Groot PG. The presence of antiphospholipid antibodies is not related to increased levels of annexin A5 in plasma. J Thromb Haemost. 2003;1:532-536.
23. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 1996;76:663-669.
24. Itabe H, Yamamoto H, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A, Imanaka T, Takano T. Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem. 1996;271:33208-33217.
25. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976;17:565-577.
26. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol concentration. J Biol Chem. 2002;277:7010-7020.
27. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, Takano T. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem. 1994;269:15274-15279.
28. Fu T, Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C- reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J. 2002;366:195-201.
29. Chang MK, Boullier A, Almazan F, Quehenberger O, Witztum IL. C-reactive protein inhibits macrophage binding of oxidized LDL. Arterioscler Thromb Vasc Biol 2003;23:a-74. Abstract.
30. Torzewski I, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
31. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 1987;111:265-269.
32. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int. 1995;45:635-641.
33. Reutelingsperger CP, van Heerde WL, Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53:527-532.
34. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184:39-51.
35. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol. 2003;14:421-430.